Recently, we reported that homozygous deletion of alternative exon 33 of Ca V 1.2 calcium channel in the mouse resulted in ventricular arrhythmias arising from increased Ca V 1.2 D33 I CaL current density in the cardiomyocytes. We wondered whether heterozygous deletion of exon 33 might produce cardiac phenotype in a dose-dependent manner, and whether the expression levels of RNA splicing factors known to regulate alternative splicing of exon 33 might change in human heart failure. Unexpectedly, we found that exon 33 C/¡ cardiomyocytes showed similar Ca V 1.2 channel properties as wild-type cardiomyocyte, even though Ca V 1.2 D33 channels exhibit a gain-in-function. In human hearts, we found that the mRNA level of splicing factor Rbfox1, but not Rbfox2, was downregulated in dilated cardiomyopathy, and CACNA1C mRNA level was dramatically decreased in the both of dilated and ischemic cardiomyopathy. These data imply Rbfox1 may be involved in the development of cardiomyopathies via regulating the alternative splicing of Ca V 1.2 exon 33. (149 words) KEYWORDS alternative splicing; cardiomyopathy; Ca V 1.2 calcium channel; heterozygous knockout; Rbfox
Introduction
Ca V 1.2 L-type calcium channels have essential roles in the cardiac excitation-contraction coupling and development. Alternative splicing in CACNA1C, encoding the Ca V 1.2 pore-forming subunit a1 C , modulates the function of Ca V 1.2 calcium channels. Exon 33 has been identified in human and rodent Ca V 1.2 a1 C subunit by transcriptscanning; 1,2 this alternative exon has been reported to affect the biochemical and biophysical functions of heterologously expressed Ca V 1.2 channels. [1] [2] [3] [4] [5] [6] Recently, we generated Ca V 1.2 exon 33 specific knockout mice (exon 33 ¡/¡ ) and these exon 33-null mice were found to develop cardiac arrhythmia and dysfunction, owing to increased Ca V 1.2 channel currents arising from a leftward shift of voltage-dependent activation and inactivation potentials as compared to wild-type (WT) (exon 33 C/C ) cardiomyocytes. 7 Thus, we asked whether cardiomyocytes isolated from heterozygous exon 33-knockout mice might produce intermediate changes in biophysical properties of the Ca V 1.2 channels and how this might affect excitability of the cardiomyocytes.
In our previous work, we found that the expression of Ca V 1.2 alternative exon 33 was significantly increased in human failing hearts, 7 and these data raise a potential relevance to clinical management of heart failure. A second question we asked was the mechanism by which alternative splicing of exon 33 of Ca V 1.2 channels might be regulated in the heart. The (U) GCAUG elements, which can be recognized and bound by RNA binding protein Rbfox1/2, were identified in the intronic sequence surrounding Ca V 1.2 exon 33.
alternative exon 33 of Ca V 1.2 calcium channels. 8, 9 To date, Rbfox1/2 was reported to be crucial in cardiac development and different cardiomyopathies via regulation of serial splicing events, [10] [11] [12] [13] [14] indicating a plausible role in the regulation of alternative exon 33 of Ca V 1.2 calcium channels in the heart. In this follow-up study of our previous work, we measured Rbfox1/2 mRNA levels in human failing and non-failing heart samples, in order to explore the possible association between the expressions of Rbfox and exon 33 of Ca V 1.2 in cardiomyopathies.
Results

Exon 33
C/¡ cardiomyocyte has similar Ca V 
Rbfox1 expression is correlated with exon 33 and CACNA1C mRNA levels in human hearts
To address the possible pathological relevance, we collected human non-failing and failing heart samples 7 to measure RBFOX1/2 and CACNA1C mRNA expression. Specifically, Rbfox1 expression in dilated cardiomyopathy (DCM) failing hearts was significantly lower than non-failing hearts (Fig. 3A) . However, Rbfox2 expression had no significant differences among non-failing, dilated and ischemic cardiomyopathy (ICM) failing hearts (Fig. 3B) . Moreover, CACNA1C mRNA expression was dramatically downregulated in both dilated and ischemic cardiomyopathy failing hearts (Fig. 3C) , implying that decreased Ca V 1.2 calcium channel may also be involved in the induction of hypertrophy and/ or heart failure. 17 More interestingly, we found that Rbfox1 expression was negatively correlated with exon 33 inclusion (Fig. 3D ), but positively correlated with CACNA1C mRNA expression in human hearts (Fig. 3E) , these suggest dysregulated Rbfox1 might play some roles in the regulation of human Ca V 1.2 expression. Therefore, it is reasonable to believe that altered Rbfox1 expression may contribute to the changes in expression and alternative splicing of Ca V 1.2 calcium channels that led to lower channel activity in failing hearts.
Discussion
Alternative splicing of Ca V 1.2 calcium channel is recognized as an important post-transcriptional modification that provides modulation of channel function. Our previous work has directly addressed the in vivo significance of altered Ca V 1.2 calcium channel property arising from alternative splicing of exon 33 that showed the deletion of exon 33 induced enhanced channel activity and abnormal cardiomyocyte excitation. This process in turn resulted in ventricular arrhythmia and cardiac dysfunction in mice. 7 In normal rodent hearts, the proportion of Ca V 1.2 calcium channels with inclusion of exon 33 is more than 90%. [2] [3] [4] 7 As such, what could the phenotype of the heart be if this proportion decreases to »50%? Here, we investigated that 50% expression at the transcript level of exon 33 in Ca V 1.2 channel in heterozygous knockout mice did not produce any significant changes in channel properties and therefore not surprisingly no gross differences in cardiac electrical properties in cardiomyocytes. Our data raised the question on how the presence of Ca V 1. channels in cardiomyocytes. There are several possibilities to explain this phenotype. First, Ca V 1.2 channels with exon 33 (Ca V 1.2 33 ) make a chief role in the excitation-contraction coupling in the normal heart, and a small portion of Ca V 1.2 33 channels is sufficient to maintain the regular activities of Ca V 1.2 channels. Second, Ca V 1.2 a1 C subunits are known to be bound with Ca V b subunits to traffic them to cell membrane; 18 though Ca V 1.2 D33 channels are transcribed in cardiomyocytes, the trafficking of these Ca V 1.2 D33 channels might be disturbed when competing with Ca V 1.2 33 channels, thus reducing the contribution of Ca V 1.2 D33 channels on the cell surface in heterozygous knockout cardiomyocytes. Third, as oligomerization of Ca V 1.2 channels can form a "coupled gating" function in excitable cells, 19, 20 Ca V 1.2 channels might have a "selective ability" to form the oligomerization with neighboring Ca V 1.2 33 channels, but not Ca V 1.2 D33 channels in cardiomyocyte; thus the exclusion of alternative exon 33 may affect the oligomerization of Ca V 1.2 channels. Nevertheless, the detailed mechanisms of Ca V 1.2 33 -Ca V 1.2 D33 channel interaction are warranted for further investigation.
Another issue is which mechanism(s) regulates the specific expression pattern of alternative exon 33 of Ca V 1.2 calcium channels in human hearts. The possible candidate is Rbfox1/2, which belong to the RNAbinding proteins, 21 it has been known to directly enhance the inclusion of alternative exon 33 of Ca V 1.2 channel during neuronal development. 8 Therefore, what is the relevance of Rbfox1/2 in the pathology of cardiac diseases? In this work, we found the expression of Rbfox1 was dramatically decreased in human DCM when compared with non-failing hearts, which is consistent with Gao's report in which they indicated the expression of Rbfox1 was markedly diminished in human DCM and in transverse aortic restrictioninduced murine heart failure. 12 These imply Rbfox1 indeed takes part in the alternative splicing regulation of diseased hearts. Although Rbfox1 was reported to enhance the inclusion of Ca V 1.2 alternative exon 33 in , in contrast we found the expression of Rbfox1 was negatively correlated with the expression of exon 33 in human hearts. This result could be considered as the increased expression of Ca V 1.2 33 channels could be a compensatory response to heart failure in humans, but we cannot exclude other potential splicing factors that might directly or indirectly regulate the alternative splicing of Ca V 1.2 exon 33 in human heart. Here, we also found the dramatic decrease of Ca V 1.2 a1 C mRNA in human DCM and ICM hearts, in line with the reduced activities of Ca V 1.2 channels in human failing hearts 22 . Moreover, the expression of Rbfox1 was positively correlated with the expression of Ca V 1.2 calcium channels in human hearts by our study. Therefore, induction of Rbfox1 expression might have some beneficial effects on the cardiomyopathies. 12 In conclusion, 50% loss of alternative exon 33 in Ca V 1.2 calcium channel did not affect the electrophysiological properties of Ca V 1.2 channels recorded in mouse cardiomyocytes, and Rbfox1 might be a modulator of exon 33 alternative splicing in human heart. Nevertheless, further studies are required to clarify the molecular mechanisms how the presence of exon 33 affect the structure and function of Ca V 1.2 channels and what upstream signals may be important to regulate Rbfox expression.
Materials and methods
Human samples and animals
Human heart samples and knockout mice of alternative exon 33 of Ca V 1.2 (exon 33 ¡/¡ ) were obtained or generated as described previously. 7 Exon 33 ¡/¡ mice were crossed with C57BL/6J mice to generate heterozygous knockout mice (exon 33
). The genotype was determined by PCR method. Isolation of cardiomyocytes was also described in our previous report. 7 All animals were treated ethically in accordance with approved institutional IACUC protocol of the National University of Singapore.
RT-PCR
Total RNA was extracted using Trizol (Invitrogen) as indicated in manufacturer's protocol. Reverse transcription was performed using Superscript III (Invitrogen). Real-time PCR was used in quantitative analysis of the Rbfox1/2 and Ca V 1.2 channel mRNA expression level. FAM labeled CACNA1C probe located at the junction of constitutive exon 3 and exon 4 (Assay ID Hs00167681_m1, Applied Biosystems), and RBFOX1/2 (Assay ID Hs01125659_m1 and Hs00204814_m1, Applied Biosystems) were used to measure the standard mRNA expressions. Human GAPDH (Assay ID 4333764T, Applied Biosystems) and RPLPO (large ribosomal protein) (Assay ID 4333761T, Applied Biosystems) were used as endogenous control (FAM TM Dye/MGB Probe, Applied Biosystems).
Electrophysiology
Whole-cell L-type calcium current and action potentials of cardiomyocytes were recorded using the patch-clamp technique as previously described. 7 
Statistical analysis
Data is reported as mean § S.E.M. Statistical significance was analyzed using a student t test, or one-way ANOVA followed by post hoc multiple comparisons test. The relationships between Rbfox1 expression and exon 33 or Ca V 1.2 expression were analyzed by linear regression. A value of P < 0.05 was considered as statistical significance.
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